Early research (Phase 1)Study completedNCT00049296What this trial is testingThalidomide and Docetaxel in Treating Patients With Advanced CancerWho this might be right forCancer Case Comprehensive Cancer Center 26
Early research (Phase 1)Looking for participantsNCT06902376What this trial is testingXL092 and Cemiplimab in BRAF WT Thyroid CancerWho this might be right forAnaplastic Thyroid CancerThyroid CancerBRAF Mutation-Related Tumors UNC Lineberger Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401What this trial is testingStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsWho this might be right forSolid TumorsCNS Tumors Hoffmann-La Roche 69
Not applicableStudy completedNCT02862470What this trial is testingAnaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer PatientsWho this might be right forThyroid Cancer National Taiwan University Hospital 22
Testing effectiveness (Phase 2)UnknownNCT06362694What this trial is testingStudy of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF TherapyWho this might be right forAnaplastic Thyroid Cancer Saint Petersburg State University, Russia 10
Large-scale testing (Phase 3)Active Not RecruitingNCT03914612What this trial is testingTesting the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerWho this might be right forEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid Adenocarcinoma+13 more National Cancer Institute (NCI) 813
Testing effectiveness (Phase 2)Study completedNCT02853318What this trial is testingPembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerWho this might be right forFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+11 more Roswell Park Cancer Institute 40
Testing effectiveness (Phase 2)Study completedNCT00389441What this trial is testingStudy Of AG-013736 In Patients With 131I-Refractory Thyroid CancerWho this might be right forThyroid Neoplasms Pfizer 52
Testing effectiveness (Phase 2)WithdrawnNCT04739566What this trial is testingDabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid CancerWho this might be right forThyroid Gland Anaplastic Carcinoma Saint Petersburg State University, Russia
Testing effectiveness (Phase 2)WithdrawnNCT04731740What this trial is testingPembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid CancerWho this might be right forMetastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaThyroid Gland Anaplastic Carcinoma by AJCC V8 Stage Saint Petersburg State University, Russia
Early research (Phase 1)Study completedNCT00002600What this trial is testingCombination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial CancerWho this might be right forFallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 23
Large-scale testing (Phase 3)Study completedNCT02737501What this trial is testingALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsWho this might be right forNon-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more Ariad Pharmaceuticals 275
Early research (Phase 1)Study completedNCT00073944What this trial is testingBCX-1777 in Treating Patients With Refractory CancerWho this might be right forCancer BioCryst Pharmaceuticals
Early research (Phase 1)Study completedNCT00006368What this trial is testingYttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerWho this might be right forBrain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT01642082What this trial is testingDalantercept in Treating Patients With Recurrent or Persistent Endometrial CancerWho this might be right forEndometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed Adenocarcinoma+6 more Gynecologic Oncology Group 28
Not applicableLooking for participantsNCT07068542What this trial is testingSacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid CancerWho this might be right forAdvanced Thyroid CarcinomaRadioiodine-refractory Differentiated Thyroid CancerPoorly Differentiated Thyroid Carcinoma Zhejiang Provincial People's Hospital 94
Early research (Phase 1)WithdrawnNCT00937417What this trial is testingS0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid TumorsWho this might be right forBreast CancerHead and Neck CancerLung Cancer+2 more SWOG Cancer Research Network
Testing effectiveness (Phase 2)Study completedNCT00004089What this trial is testingChemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid CancerWho this might be right forHead and Neck Cancer National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT00354601What this trial is testingDocetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity CancerWho this might be right forFallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer Wake Forest University Health Sciences 2
Testing effectiveness (Phase 2)Ended earlyNCT02521051What this trial is testingPhase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer (NSCLC) Massachusetts General Hospital 11